DEX-implant (46 eyes) | Bevacizumab (42 eyes) | P value | |
Number of eyes that underwent glaucoma surgery (0–5 years) | 1 (2%) | 1 (2%) | 0.95 |
Number of eyes that had cataract surgery (0–5 years) (% of phakic enrolled eyes) | 26 (87) | 23 (72) | 0.86 |
Number of eyes that were NPDR at baseline who progressed to PDR (0–5 years) | 6/31 | 1/32 | <0.05 |
Average number of treatments for 5-year completers (26 eyes in each group), n (SD) | 9.0 (6.04) | 19.2 (7.04) | <0.05 |
DEX, dexamethasone; NPDR, non-proliferative diabetic retinopathy.